Shares of Eli Lilly finished Friday up about 1.3%, closing at $1,037.15. The boost came after the company unveiled a $3.5 billion plan for a new manufacturing facility in Pennsylvania. This plant will produce injectable weight-loss drugs, including retatrutide—a next-gen medication Lilly says has outperformed Zepbound. “All these sites, including this one, will be really state of the art manufacturing to last many decades to come,” CEO David Ricks said in Allentown. Drugmakers like Pfizer and Merck & Co are also expanding U.S. capacity amid Donald Trump’s threat of import tariffs. Meanwhile, Lilly is racing Novo Nordisk for U.S. approval of an oral weight-loss pill, which it plans to price at $150 a month and launch in several countries.
